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Background. Depression and anxiety in Parkinson’s disease are common and frequently co-morbid, with signiﬁcant im-
pact on health outcome. Nevertheless, management is complex and often suboptimal. The existence of clinical subtypes
would support stratiﬁed approaches in both research and treatment.
Method. Five hundred and thirteen patients with Parkinson’s disease were assessed annually for up to 4 years. Latent
transition analysis (LTA) was used to identify classes that may conform to clinically meaningful subgroups, transitions
between those classes over time, and baseline clinical and demographic features that predict common trajectories.
Results. In total, 64.1% of the sample remained in the study at year 4. LTA identiﬁed four classes, a ‘Psychologically
healthy’ class (approximately 50%), and three classes associated with psychological distress: one with moderate anxiety
alone (approximately 20%), and two with moderate levels of depression plus moderate or severe anxiety. Class member-
ship tended to be stable across years, with only about 15% of individuals transitioning between the healthy class and one
of the distress classes. Stable distress was predicted by higher baseline depression and psychiatric history and younger
age of onset of Parkinson’s disease. Those with younger age of onset were also more likely to become distressed over the
course of the study.
Conclusions. Psychopathology was characterized by relatively stable anxiety or anxious-depression over the 4-year
period. Anxiety, with or without depression, appears to be the prominent psychopathological phenotype in
Parkinson’s disease suggesting a pressing need to understanding its mechanisms and improve management.
Received 13 March 2015; Revised 27 August 2015; Accepted 21 September 2015
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Introduction
Depression and anxiety are common in Parkinson’s
disease (PD) (Reijnders et al. 2008; Dissanayaka et
al. 2010), frequently co-occur (Nuti et al. 2004;
Negre-Pages et al. 2010) and are associated with care
dependency, poor work and social function, and
reduced health-related quality of life (Schrag et al.
2000; Riedel et al. 2012; Armstrong et al. 2014; Chen
& Marsh, 2014; Duncan et al. 2014). Depression is
further associated with faster rate of physical and cog-
nitive decline (Starkstein et al. 1992), increased demen-
tia risk (Tandberg et al. 1996) and higher mortality
(Hughes et al. 2004). Despite these facts, good quality
evidence for the management of depression is only re-
cently emerging (Dobkin et al. 2011; Richard et al. 2012)
with a recognized paucity of evidence to guide the
treatment of anxiety (Seppi et al. 2011; Deane et al.
2014).
PD is heterogeneous in symptoms and clinical
course, suggesting possible pathophysiological disease
subtypes and the opportunity to apply stratiﬁed treat-
ment approaches to improve outcome (Seppi et al.
2011; Berg et al. 2013, 2014). We previously reported
a comprehensive cross-sectional assessment of mood
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and mood-related symptoms in a cohort of 513 patients
(Prospective Study of Mood State in Parkinson’s dis-
ease: PROMS-PD; Brown et al. 2011). Latent class
analysis (LCA) identiﬁed four classes interpreted
as: psychologically healthy with low probability of
clinically prominent depression and anxiety related
symptoms (‘Psychologically healthy’, 60.4%); one char-
acterized by anxiety-related symptoms (‘Anxious’,
22.0%); one with predominantly depressive symptoms
(‘Depressed’, 9.0%) and ﬁnally a class with both anx-
iety and depressive symptoms (‘Anxious depressed’,
8.6%). The latter two classes differed on a range of
demographic and clinical variables, suggesting that
PD depression may be heterogeneous (Brown et al.
2011; Burn et al. 2012). This paper reports a longitudin-
al extension of our 2011 study, employing assessment
over a 4-year period to permit a more reliable assess-
ment of mood-related subtypes; characterize change
in depressive and anxious symptomatology as the dis-
ease progresses, and examine associated clinical and
demographic features.
Method
Longitudinal PD cohort
PROMS-PD (UKCRN ID 2519) recruited participants
over a 14-month period from specialist PD or move-
ment disorder outpatient clinics across the UK
(Brown et al. 2011). Eligibility criteria at inclusion
were a clinical diagnosis of idiopathic PD, the ability
to provide informed consent at entry and living within
travelling distance from a study centre. Entry exclusion
criteria were sensory loss or communication difﬁculty
sufﬁcient to interfere with assessment. After baseline
assessment (year 1) participants were re-contacted
6-monthly and assessed annually. Drop-out at each
contact was classiﬁed as death; not-assessable or with-
drawal from the study due to worsening of physical or
mental health or cognitive impairment; withdrawal for
other reasons; loss of contact or moved out of area, and
change in primary diagnosis.
Baseline clinical and demographic measures
Participants were assessed as described in full else-
where (Brown et al. 2011; Burn et al. 2012).
Demographic information included gender, current
age and socio-economic status (Ofﬁce for National
Statistics, 2000). Disease-related variables included
age of PD onset, side of PD symptom onset and current
antiparkinsonian medication from which a L-dopa
equivalent daily dose (LEDD) was calculated
(Tomlinson et al. 2010). Motor disability, symptom
severity and motor complications were assessed
using the Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS; Fahn et al. 1987) parts II-IV, plus the Hoehn
and Yahr Scale (Hoehn & Yahr, 1967), and Schwab
and England Scale (Schwab & England, 1969). Rate
of progression of motor symptoms at baseline (Lewis
et al. 2005) and motor phenotype [Postural Instability
and Gait (PIGD) or Tremor-Dominant/Indeterminate]
were derived from the UPDRS (Jankovic et al. 1990).
Cognition was assessed using the Addenbrooke’s
Cognitive Examination – Revised (ACE-R; Mioshi
et al. 2006), an extended mental status examination
assessing a range of neuropsychological processes rele-
vant to PD. Burden of health complaint was assessed
using the Duke University Older Americans
Resources and Services (OARS) physical health mea-
sure (Whitelaw & Liang, 1991), including a checklist
of physical health complaints common in older adults.
Assessment of depressive- and anxiety-related
symptoms
Each year, depressive, anxiety and related symptoms
were assessed using a semi-structured interview
based on the Geriatric Mental State (GMS; Copeland
et al. 1976). Symptoms were rated and then recoded
as ‘prominent’ (1) or ‘absent/normal’ or ‘present but
not prominent’ (0). Analyses were restricted to 26
GMS items reported as prominent in at least 2% of
the sample at baseline (see Fig. 1). Depression severity
was assessed with the Hamilton Depression Rating
Scale (HAMD; Hamilton, 1960). The Hospital Anxiety
and Depression Scale (HADS) was used for self-report
(Zigmond & Snaith, 1983). A history of depressive or
anxiety disorder was ascertained by interview.
Latent transition analyses (LTAs)
LTA is an extension of LCA which assumes that there
exist unobserved (latent) categorical variables (classes)
that explain the associations between observed mea-
sures. Two sets of parameters are estimated: (i) prob-
abilities describing the marginal distribution of the
latent classes at baseline and transition probabilities
between latent classes over time and (ii) conditional
probabilities, i.e. probabilities that a symptom is pre-
sent given the participant belongs to a class. LTAs
(Graham et al. 1991; Collins & Lanza, 2010) were car-
ried out to identify depression and anxiety related sub-
types in PD, characterize their proﬁles and describe
change over time (transitions). Our LTA approach is
similar to that used elsewhere (Lamers et al. 2012).
Speciﬁcally, we ﬁt LTA models to a matrix of 513
patients on 26 binary GMS symptom scores at each
of four annual time-points. We refer to the probabilities
across the GMS items as the class proﬁles and use them
for interpretation and labelling.
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We assume that class proﬁles themselves do not
vary over time, although we tested this assumption
empirically by comparing the ﬁt to that of a model
that allowed all the conditional probabilities to vary
(Collins & Lanza, 2010). As the LTAs carried out here
were extensions of an LCA performed on the cross-
sectional baseline data (Brown et al. 2011), we planned
to ﬁt a four-class model, but also re-assessed the num-
ber of classes empirically using several model ﬁt
indices.
We wished to employ all the available GMS data in
the LTA modelling but without relying on the restrict-
ive assumption that GMS scores were missing com-
pletely at random (MCAR). Instead we used survival
analysis to identify baseline variables that predicted
drop-out from the study and then extended the LTA
model to include these variables by allowing them to
predict class membership at each time point. The
derived parameter estimates are valid under a less
restrictive missing at random (MAR) assumption.
Drop-out was measured every 6-month interval with
time intervals frequently being right-censored. Com-
plementary log-log regression was used to model the
effect of a baseline variable on the hazard of drop-
ping out in the next 6-month interval given that a par-
ticipant is still in the study (Prentice & Gloeckler, 1978).
The approach relies on a proportional hazards assump-
tion. The effect of each putative baseline predictor of
drop-out was assessed separately resulting in a largish
list of empirically identiﬁed predictors. A smaller repre-
sentative predictor subset was identiﬁed for inclusion
in the LTA choosing individual predictors that repre-
sented subsets of correlated predictors.
Stepwise multinomial logistic regression was used to
assess whether baseline variables could predict path
memberships of interest. A list of putative baseline pre-
dictors representing different constructs was used and
a best prediction model established by forward vari-
able selection. The forward variable selection was car-
ried out by initially ﬁtting multinomial logistic
regression models with each predictor as a single cov-
ariate and selecting the best predictor by comparing
the χ2 goodness-of-ﬁt statistic. At each subsequent
stage the effect of adding each of the remaining predic-
tors to the model was assessed using a likelihood ratio
test and the next best predictor selected on the basis of
statistical signiﬁcance. The procedure was terminated
when the likelihood ratio test was no longer signiﬁcant
for any of the remaining predictors.
Statistical analyses were carried out in Stata v. 11
(StataCorp, 2009) and Mplus v. 7 (Muthen &
Muthen, 2007).
Ethical standards
The authors assert that all procedures contributing to
this work comply with the ethical standards of the rele-
vant national and institutional committees on human
experimentation and with the Helsinki Declaration of
1975, as revised in 2008. (Ethics reference 07/MRE01/9).
Results
Sample characteristics and longitudinal GMS
assessments
Of 941 patients invited to participate, 525 consented
but 12 withdrew before baseline assessment. The base-
line sample (N = 513) has been described previously
(Brown et al. 2011; Burn et al. 2012). Brieﬂy, there was
Fig. 1. Observed Geriatric Mental State prominent symptom frequencies by year.
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a wide range of PD duration and severity, although a
majority were Hoehn and Yahr stages II–III with a
non-tremor dominant motor proﬁle. Almost all (95%)
were taking antiparkinsonian drugs. About a third of
the sample showed evidence of cognitive impairment.
Analysable data were available from 458 (89.2%) at
year 2, 395 (77.0%) at year 3 and 329 (64.1%) at year
4 (see Supplementary Fig. S1). There were 44 (8.6%)
deaths; 45 (8.8%) became unassessable or withdrew
from the study on health grounds; 48 (9.4%) withdrew
for other reasons (e.g. too busy, no longer interested or
no reason given), while 42 (8.2%) moved away or were
uncontactable. Ten (1.9%) were re-diagnosed with ei-
ther essential tremor (N = 3), progressive supranuclear
palsy (N = 1), multiple system atrophy (N = 4) or had
undergone a negative dopamine transporter scan
(N = 2). As these numbers were small and all partici-
pants met diagnostic criteria at inclusion, they were
retained in the analysis to better reﬂect the reality of
the clinical setting.
The observed characteristics of the remaining sample
at each time point were not subject to formal statistical
comparison, and interpretation is subject to the effects
of non-random drop-out. Nevertheless, the data indi-
cated disease progression as evidenced by worsening
of observed mean UPDRS scores, Hoehn and Yahr
stages and increasing LEDD (see Supplementary
Table S1). The overall rate of observed depression
(HAMD 510) increased from 20.5% at baseline to
24.1% of those remaining in the study at year 4,
while use of antidepressant/anxiolytic medication
increased from 23.5% to 30.4% over the same period.
Fig. 1 shows the proﬁle of observed frequencies of
prominent GMS symptoms at each assessment point.
Consistently over time the most common symptoms
were worry, subjective tension and restlessness and fa-
tigue with an observed prevalence of 530% followed
by poor concentration, irritability, symptoms of gen-
eral anxiety and panic and loneliness. Other symptoms
were observed in420% of the total sample across the 4
years.
LTA-deﬁned PD subtypes
Table 1 shows ﬁt indices for different numbers of
classes based on the binary GMS scores alone.
Akaike’s Information Criterion (AIC) and sample size
adjusted Bayesian Information Criterion (BIC) indicate
the best ﬁt for six classes, while the BIC and entropy
support a four-class solution. We selected the latter
as the most interpretable, for consistency with our pre-
vious LCA solution and to avoid small classes contain-
ing <5% of participants.
Model ﬁt indices for a model assuming full param-
eter invariance (AIC 22 834, BIC 23 736, sample size
adjusted BIC 23 053) were better than those of a
model that allowed class proﬁles to vary over time
(AIC 23 601, BIC 25 271, sample size adjusted BIC 23
599). Thus, we continued to assume that class proﬁles
did not vary and use the estimated conditional prob-
abilities to summarize depressive and anxiety symp-
toms within classes.
The following baseline variables were associated
with earlier drop-out (hazard ratios that differed
from 1 (p < 0.05) in the complementary log-log regres-
sions): older age, later age of PD onset, longer PD dur-
ation, higher UPDRS-III score, higher HAMD score,
higher HADS anxiety and depression scores, lower
ACE-R score, worse Schwab and England score, and
Hoehn and Yahr stages IV or V. To reﬂect these corre-
lated concepts in the LTA models, age at baseline, dur-
ation of PD, UPDRS-III score, HADS anxiety and
depression and ACE-R score were selected for
inclusion.
Interpretation of the LTA model was based on exam-
ination of the symptom proﬁles for the four latent
classes (see Fig. 2). The ﬁrst class (open circles) repre-
sents a high predicted probability (0.60–1.00) of anxiety
symptoms, particularly subjective tension and worry,
symptoms of generalized anxiety/panic, autonomic
symptoms of anxiety, irritability and poor concentra-
tion. Other common symptoms (probability 0.40–0.59)
included fatigue, depressed mood, crying, indecisive-
ness and slowed thinking. This class is labelled ‘High
anxiety + depression’. Class 2 (solid circles), shows a
similar proﬁle but with lower probabilities of the
main anxiety-related symptoms and is labelled
‘Moderate anxiety + depression’. Class 3 (open squares)
is characterized mainly by moderate probabilities of
anxiety symptoms without evident depression and is
Table 1. Information criteria and entropies for ﬁtted LTA models
with different numbers of classes
No. of
classes AIC BIC
Sample size
adjusted
BIC Entropy
2 24 896 25 146 24 959 0.867
3 24 215 24 631 24 320 0.829
4 23 892 24 499 24 045 0.836
5 23 711 24 534 23 918 0.809
6 23 575 24 640 23 843 0.830
LTA, Latent transition analysis; AIC, Akaike’s Information
Criterion; BIC, Bayesian Information Criterion.
For the ﬁrst three indices (AIC, BIC, sample size adjusted
BIC) a lower value indicates a better model ﬁt. Entropy
measures how well participants are classiﬁed with higher
values indicating better classiﬁcation.
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labelled ‘Moderate anxiety’. Finally, class 4 (solid
squares) was characterized by low probability of any
prominent symptoms and labelled ‘Psychologically
healthy’.
The four-class LCA solution derived using the entire
4 years varies somewhat from our previous LTA solu-
tion from the baseline data alone (Brown et al. 2011). A
cross-tabulation of the classiﬁcations at baseline
revealed that the solutions matched for 87% of the
sample with high correspondence (93%) for the
‘Psychologically healthy’ in the two analyses.
Similarly 87% of those allocated to the LCA ‘Anxiety’
class were allocated to the LTA ‘Moderate anxiety’
class. For the two smaller classes, 59% of those previ-
ously labelled by LCA ‘Anxious depressed’ were
now allocated to the ‘High anxiety + depression’ LTA
class and 38% to ‘Moderate anxiety + depression’.
Similarly, 64% of those in the original LCA class
‘Depressed’ ended up in the new ‘Moderate anxiety
+ depression’ LTA class, while 23% were labelled
‘Moderate anxiety’.
Because of the association between higher levels of
depression and anxiety at baseline and subsequent
loss to follow-up we would expect different drop-out
rates across the four classes. However, the inclusion
of predictors of drop-out in the LTA model means
that such differential drop-out would not affect the
analysis or interpretation of the results.
Transitions between PD subtypes and trajectory
paths
Fig. 3 shows the estimated marginal proportions of the
four classes at each time-point. The ‘Psychologically
healthy’ class was most common, followed by the
‘Moderate anxiety’ class, and two anxious and
depressed classes. There was a trend towards an in-
crease in the combined depression-related classes,
from 15.1% at baseline to 19.5–21.1% in subsequent
years, while the ‘Moderate anxiety’ class showed a cor-
responding decrease.
We used the ﬁtted LTA model to classify every pa-
tient at each time-point according to their maximum
posterior estimated class probability. Observed trajec-
tories are represented graphically in Fig. 4 (see also
Supplementary Table S3). The most common paths
were those with membership of the same class
over adjacent years. Overall, an estimated 51.1%
Fig. 2. Estimated proﬁles of depression- and anxiety-related Parkinson’s disease latent transition analysis classes.
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[95% conﬁdence interval (CI) 46.7–55.6] remained in
the ‘Psychologically healthy’ class throughout the 4
years (which we call the ‘Remaining healthy’ path)
while 33.7% (95% CI 29.5–38.0) stayed in one or
other of the remaining classes (‘Remaining distressed’
path). Only 8.6% (95% CI 6.1–11.1) initially healthy
were reclassiﬁed into one of the other classes
(‘Becoming distressed’ path), while 6.5% (95% CI 4.3–
9.7), of those initially ‘distressed’ were later reclassiﬁed
as ‘Psychologically healthy’ (‘Becoming well’ path).
Baseline predictors of trajectory paths
What predicts membership of these paths? Because we
were modelling longitudinal patterns of change in the
context of a chronic and progressive condition we lim-
ited the analysis to the ‘Remaining distressed’ and
‘Becoming distressed’ paths with ‘Remaining healthy’
as the reference path. Additionally, it was assumed
that ‘Becoming well’ might reﬂect successful manage-
ment of the depression and/or anxiety rather than
reﬂecting particular baseline characteristics.
The following list of baseline demographic and clin-
ical variables were considered a priori as potential pre-
dictors of trajectory paths: gender, age, age of onset of
PD, LEDD, UPDRS-III, PD motor phenotype, esti-
mated rate of progression of motor symptoms, pres-
ence of motor ﬂuctuations, depression severity
(HAMD), cognitive function (ACE-R), burden of phys-
ical health conditions (OARS), socio-economic status
(NS-SEC) and history of psychiatric illness. The ﬁnal
model included HAMD score, age of PD onset and his-
tory of past mental illness as predictors of trajectory
paths [model ﬁt likelihood ratio χ2(6) = 194.33, p <
0.0001, pseudo-r2 = 0.238]. Younger age of onset pre-
dicted being on the ‘Becoming distressed’ path relative
to ‘Remaining healthy’ [odds ratio (OR) per extra year =
0.95, 95% CI 0.93–0.98, z =−3.29, p < 0.001] (i.e. for every
year older at PD onset there was a 5% lower risk of be-
coming distressed having been psychologically healthy
initially). ‘Remaining distressed’ was predicted by
higher baseline HAMD (OR per extra point on scale =
1.35, 95% CI 1.27–1.44, z = 9.28, p < 0.001), younger age
of PD onset (OR 0.97, 95% CI 0.95–0.99, z =−2.75, p =
0.01) and history of past psychiatric illness (OR 2.17,
95% CI 1.23–3.83, z = 2.68, p = 0.01).
It should be noted that this analysis is limited to
baseline predictors of broadly deﬁned paths. We did
not consider the large number of potential individual
transitions, nor factors that may have changed in the
preceding 12 months before each assessment. Thus
changes in medication and health status, life events,
etc. may have additionally explained some of the indi-
vidual transitions observed.
Discussion
We consider here the present ﬁndings in relation to our
previous cross-sectional analysis and subtype classiﬁca-
tion (Brown et al. 2011) before discussing the results in
the context of other longitudinal studies of depression
and anxiety in PD. We then consider the implications
for our conceptualization of depression and anxiety, its
clinical management and directions for future research.
The LTA enhances our previous work investigating
latent classes at a single time point (Brown et al. 2011)
Fig. 3. Estimated proportions (%) of latent transition
analysis class membership at each time-point.
Fig. 4. Estimated frequencies of class transitions. The
thickness of each black connecting bar (or dashed line)
is proportional to the estimated transition frequency.
Numerical frequencies are shown where >40%. Dashed lines
indicate frequencies of 5–10%. For clarity, class transition
frequencies of <5% are not shown (see Supplementary
Table S3 for full numerical data).
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as it makes use of all available data over an extended
period of cohort observation incorporating baseline pre-
dictors of missingness. The proﬁles of the four-class
solutions from the present LTAs were broadly similar
to those from the previous, but more restricted, LCA
with close agreement in class membership. They dif-
fered in that the ‘Depressed’ class proﬁle was better
characterized as ‘Moderate anxiety + depression’. This
differed from the ‘High anxiety + depression’ class
proﬁle mainly in the prominence of anxiety symptoms
(Fig. 2). The existence of two anxious-depressed classes
(comprising almost 20% of our sample by year 4) and a
further 20% anxious patients (class 3), points strongly to
anxiety being the most prevalent and prominent
mood-related non-motor feature of PD (Fig. 3), co-
occurring 50% of the time with depressive symptoms.
It is notable that the rates of anxiety-related symp-
tom proﬁles over the years (40–45%) was higher than
the prevalence of anxiety indicated by the HADS
(Anxiety score 511) of 20–25% (Supplementary
Table S2). This may reﬂect differences in the nature
of the assessment (clinician rated using semi-
structured interview for the GMS and self-report for
the HADS) or a lower sensitivity to detect clinically
meaningful symptomatology from the HADS. How-
ever, the results indicate that evidence derived from
the HADS, and potentially other self-report scales,
may underestimate the burden of prominent anxiety-
related symptomatology in PD.
The close association between depression and anx-
iety observed here is consistent with previous ﬁndings
that two-thirds of PD patients with a depressive dis-
order had a co-morbid anxiety disorder (Menza et al.
1993), and that the presence of depression was asso-
ciated with a ﬁve-fold increased risk of co-morbid anx-
iety (Qureshi et al. 2012). Importantly, our current
data-driven methods failed to identify a class with a
proﬁle characterized by predominantly depressive
symptoms. As such, the present results do not support
the existence of depression subtypes with potentially
different aetiologies and mechanisms and so requiring
different treatments. Rather, the empirically deﬁned
PD subgroups are better characterized by the severity
of anxiety symptoms and the presence or absence of
co-occurring depression. However, the lack of a non-
anxious depressed class in the LTA does not imply
that depression without anxiety is absent in PD. The
LTA classes are deﬁned on the basis of a proﬁle of
symptom probabilities and do not indicate the absolute
presence of absence of a symptom. Additionally, con-
straining the model to four classes may have masked
smaller groupings that would have emerged if the
model had allowed for a larger number of classes.
The validity of this LTA depends upon the assump-
tion that the data are missing at random, i.e. that the
probability of being missing is dependent only on vari-
ables which are incorporated by the model. This as-
sumption is reasonable as the additional variables
included as predictors of latent classes capture reasons
for drop-out, in particular worsening health or death.
Other reasons for drop-out, such as having moved
out of the area, may be viewed as chance occurrences.
It is acknowledged that additional factors inﬂuencing
drop-out may have been missed, which would intro-
duced bias. We have assumed that any such bias will
be relatively small and as such will be more than com-
pensated for by the gains made from using all the
available data.
Although not the primary aim, the present report
provides novel prospective data on the natural history
of depression and anxiety in a large, well characterized
cohort. The observed symptoms showed a remarkably
consistent proﬁle over the four time-points (Fig. 1).
There was relatively little change in individual symp-
tom prevalence, and observed overall mean depression
and anxiety severity as indicated by the mean HADS
and HAMD scores remained relatively stable (see
Supplementary Table S1). However categorically de-
ﬁned depression (HAMD 510) did increase slightly
from 20.5% of the sample at baseline to 24.1% of those
remaining in the study after 4 years. In one of the few
previously published longitudinal studies (DATATOP),
795 newly diagnosed PD patients were followed for
up to 7 years, by which time an estimated 24% scored
510 on the HAMD (Vu et al. 2012). Depression was
also relatively stable in an earlier 12-month longitudinal
study (Starkstein et al. 1992).
An important contribution of this study is the char-
acterization of change over time in terms of transitions
between mood-related classes. Examination of the data
and analyses revealed a predominant tendency for sta-
bility rather than change (Fig. 4 and Supplementary
Table S3). In particular over 50% of the cohort
remained in the psychologically healthy class over
the entire 4 years of study, despite facing the likely
challenge of a progressive condition and prospect of
future worsening. A proportion (13.7% in year 1, to
23.5% in year 4) were taking antidepressant/anxiolytics
and so, for some, psychological health may indicate
successful treatment outcome. For the remainder, how-
ever, it is likely to reﬂect other factors. Resilience is a
multidimensional construct that allows individuals to
navigate and respond to the challenges of a chronic
stressor such as disease to protect life-satisfaction and
well-being. Social and lifestyle factors such as social
networks and physical activity may play a role, while
adaptive illness beliefs and coping style can play an
important role in buffering the effects of disease, either
the greater active use of problem-orientated coping, or
lesser reliance on strategies involving avoidance or
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emotion (Evans & Norman, 2009; Hurt et al. 2011,
2012). Complex biologically and environmentally
determined dispositional characteristics (traits) may
also play a protective role including optimism (Hurt
et al. 2013; Gison et al. 2014) or a lifelong low tendency
to engage in worry or rumination in response to stres-
sors and threats (Michl et al. 2013). At a more funda-
mental level there is growing interest in how low
biological sensitivity of the hypothalamic-pituitary-
adrenal axis and sympathetic nervous system to stres-
sors may be protective, and amenable to behavioural
interventions such as physical exercise (Silverman &
Deuster, 2014).
Just as psychologically healthy individuals tended to
remain so over the course of the 4 years, we showed
that those with prominent symptoms of anxiety and/
or depression at baseline tended to remain psycho-
logically distressed. Antidepressant/anxiolytic use, al-
though higher than in the psychologically healthy
class, was still less than might be expected (see
Supplementary Table S3) suggesting possible under-
recognition or under-treatment by clinicians as re-
ported elsewhere (Shulman et al. 2002; Weintraub
et al. 2003), or patient reluctance to take more medica-
tion (Dobkin et al. 2013). Prolonged distress might also
indicate the presence of vulnerability factors opposite
to those associated with resilience. Although not a
comprehensive assessment, our analysis identiﬁed
only younger age of onset, higher baseline depression
levels and a prior history of depressive illness as the
main predictors of persistent psychological morbidity
relative to continued health. Other demographic and
PD-related factors such as higher LEDD, the presence
of motor ﬂuctuations, cognitive impairment and
motor phenotype were not predictive once the effect
of the above three variables was accounted for. Few
participants became distressed, having been well ini-
tially and only younger age of onset predicted this tra-
jectory. However, this reinforces the vulnerability of
this group and the need for clinical vigilance.
Consistent with evidence that anxiety increases the
risk of depression onset or relapse in older adults
(Andreescu et al. 2007) 25.7% (n = 29) of those in our
‘Moderate anxiety’ class in year 1 transitioned into
one of the two anxiety + depression classes in year 2
(Supplementary Table S3). At the same time 36.1%
(n = 31) transitioned in the opposite direction, suggest-
ing a remission of depression but with signiﬁcant re-
sidual anxiety.
It should be noted that the reported evidence on sta-
bility and transitions needs to be interpreted in the con-
text of the 12-month assessment intervals. This means
that shorter term transitions (e.g. from psychologically
healthy to distressed and back to healthy) would not
have been detected.
What are the implications of these ﬁndings for treat-
ment and the design of clinical trials? Good quality
evidence for the efﬁcacy of pharmacotherapy for de-
pression remains limited, inconsistent and indicates
only low to moderate effect sizes (Weintraub et al.
2005; Menza et al. 2009). In the largest trial to date
(SAD-PD), signiﬁcant effects were observed for mean
depression severity change at 12 weeks treatment
with paroxetine and venlafaxine XR. However, re-
sponse and remission rates did not differ from placebo
(Richard et al. 2012). However a third or more of those
receiving active treatment failed to show a clinical re-
sponse (550% decrease in HAM-D) (32% paroxetine,
47% venlafaxine), while the majority failed to remit
(deﬁned as HAMD47) (56% paroxetine and 63% ven-
lafaxine). These results are consistent with other de-
pression RCTs in older adults. Low remission and
response rates are typical and associated with factors
including co-morbid physical health conditions and
cognitive change, particularly executive dysfunction
(Alexopoulos et al. 2002), both very relevant to PD. A
further predictor of poor treatment outcome is co-
morbid anxiety. In the SAD-PD trial, high anxiety pre-
dicted worse antidepressant response (Moonen et al.
2014), a ﬁnding shown in RCTs of non-PD depression
(Fava et al. 2008; Penninx et al. 2011) including in late-
life depression (Andreescu et al. 2007; Cohen et al.
2009). Relapse rates tend to be high in such cases, per-
haps because of a larger burden of side effects and
lower compliance with maintenance therapy. While
future antidepressant trials might seek to exclude
patients with signiﬁcant anxiety to evaluate their ef-
fectiveness in ‘pure’ depression, such evidence may
be of limited value to guide the treatment of depres-
sion in PD where current evidence suggests that anx-
iety is such a prominent accompaniment.
Clinically, we need to be vigilant not just for the
presence of depression, but the symptoms of anxiety
and associated risk factors. As well as being a source
of distress and disability, evident anxiety may indicate
the possible presence of unrecognized depression, an
increased risk of future depression and poor treatment
outcome. For research, we need a far better under-
standing of the factors associated with onset, mainten-
ance and outcome of anxiety if it is a characteristic
component of the mood phenotypes in PD. Currently,
our understanding of anxiety and its treatment lags
far behind that of depression (Seppi et al. 2011), with
no clinical trials to date with anxiety as the target
and none in progress (ClinicalTrials.gov). This eviden-
tial gap was powerfully illustrated in the results of a re-
cent systematic exercise to identify current gaps in
clinical management commissioned by Parkinson’s
UK (Deane et al. 2014). Involving patients, carers, fam-
ily members and health and social care professionals, it
8 S. Landau et al.
ranked ‘reducing stress and anxiety’ second in terms of
evidential uncertainty below the management of bal-
ance and falls and above a wide range of other
motor and non-motor symptoms. What form such
treatment might take remains unclear without the
underpinning research, but might best encompass a
broad based, stepped-care approach with a combin-
ation of targeted psychological and pharmacological
interventions.
Conclusions
The present study highlights the prevalence and poten-
tial clinical signiﬁcance of anxiety-related symptoms in
PD psychopathology, either in relative isolation or in
the presence of depressive symptoms. A high level of
stability is observed over time, both good psycholog-
ical health pointing to resilience in some patients, but
also in sustained psychological distress in many others
extending over periods of years despite the best efforts
of healthcare professionals. The need for better man-
agement of anxiety symptoms is becoming recognized
and may be key to improving patient outcome.
Primary trials of pharmacological and psychological
treatments for anxiety are urgently needed, in addition
to research into risk, aetiological and maintaining
factors.
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